Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William B. Hillegass has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Relations of Life’s Essential 8 Score with Arterial and Microvascular Function: The Jackson Heart Study

    by Arko S. Dhar, William Barry Hillegass, Leroy L. Cooper, Abu Yusuf Ansari, Ramachandran S. Vasan, Gary F. Mitchell, Ervin R. Fox

    Background: Cardiovascular disease (CVD) poses a major burden on the US population, disproportionately impacting African Americans. Vascular function provides a window to assess cumulative risk predisposing individuals to adverse cardiovascular events. The American Heart Association (AHA) Life’s Essential 8 (LE8) provides a means of scoring cardiovascular health, but has yet to be correlated with vascular function. Methods: In a sample of Jackson Heart Study participants (N=2,186, mean age 57 years, 65% women), LE8 scores were calculated per AHA guidelines at baseline visits (2000-2004). Noninvasive vascular assessments using arterial tonometry and Doppler ultrasound were performed within an ancillary study (2012-2017). Tests measuring aortic and peripheral arterial stiffness included carotid-femoral pulse wave velocity, carotid brachial pulse wave velocity, carotid-radial pulse wave velocity, central pulse pressure, forward pressure wave, and characteristic impedance. Microvascular function tests included baseline and hyperemic brachial artery flow. Linear regression models, adjusted for age, age 2 , sex and heart rate, examined the association between LE8 score (independent variable) and vascular function (dependent variables). Results: In adjusted models, higher LE8 scores were associated with lower carotid-femoral pulse wave velocity (β= -0.32; 95% confidence interval (CI), [-0.42, -0.21]; p p =0.0024)), forward pressure wave amplitude (β= - 0.21; 95% CI, [-0.26, -0.16]; p p p =0.021)). Higher LE8 scores were associated with higher brachial hyperemic flow (β= 0.095; 95% CI, [0.035, 0.16]; p =0.0018)). When jointly considering the LE8 components in an adjusted model, blood glucose and pressure were most significantly associated with vascular function parameters. Conclusions: Our cross-sectional findings support the concept that a healthy lifestyle is associated with better vascular function. Future longitudinal studies are warranted to investigate whether improving LE8 scores lead to improved vascular function. Highlights: A higher AHA Life’s Essential 8 score is significantly associated with lower central artery stiffness and improved microvascular function cross-sectionally. Blood glucose and blood pressure are the Life’s Essential 8 components that are significantly associated with change across the most vascular function measures assessed in this study.

  • Open Access

    Associations between COVID‐19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS‐CoV‐2 variants

    by A. Jerrod Anzalone, William H. Beasley, Kimberly Murray, William B. Hillegass, Makayla Schissel, Michael T. Vest, Scott A. Chapman, Ronald Horswell, Lucio Miele, J. Zachary Porterfield, et al.

    Purpose: To investigate the enduring disparities in adverse COVID‐19 events between urban and rural communities in the United States, focusing on the effects of SARS‐CoV‐2 vaccination and therapeutic advances on patient outcomes. Methods: Using National COVID Cohort Collaborative (N3C) data from 2021 to 2023, this retrospective cohort study examined COVID‐19 hospitalization, inpatient death, and other adverse events. Populations were categorized into urban, urban‐adjacent rural (UAR), and nonurban‐adjacent rural (NAR). Adjustments included demographics, variant‐dominant waves, comorbidities, region, and SARS‐CoV‐2 treatment and vaccination. Statistical methods included Kaplan‐Meier survival estimates, multivariable logistic, and Cox regression. Findings: The study included 3,018,646 patients, with rural residents constituting 506,204. These rural dwellers were older, had more comorbidities, and were less vaccinated than their urban counterparts. Adjusted analyses revealed higher hospitalization odds in UAR and NAR (aOR 1.07 [1.05–1.08] and 1.06 [1.03–1.08]), greater inpatient death hazard (aHR 1.30 [1.26–1.35] UAR and 1.37 [1.30–1.45] NAR), and greater risk of other adverse events compared to urban dwellers. Delta increased, while Omicron decreased, inpatient adverse events relative to pre‐Delta, with rural disparities persisting throughout. Treatment effectiveness and vaccination were similarly protective across all cohorts, but dexamethasone post‐ventilation was effective only in urban areas. Nirmatrelvir/ritonavir and molnupiravir better protected rural residents against hospitalization. Conclusions: Despite advancements in treatment and vaccinations, disparities in adverse COVID‐19 outcomes persist between urban and rural communities. The effectiveness of some therapeutic agents appears to vary based on rurality, suggesting a nuanced relationship between treatment and geographic location while highlighting the need for targeted rural health care strategies.


  • Genetic variants and effect modifiers of QT interval prolongation in patients with sickle cell disease

    by Mengna Zhang, William B. Hillegass, Xue Yu, Suvankar Majumdar, J. Daryl Pollard, Erin Jackson, Jarrod Knudson, Douglas Wolfe, Gregory J. Kato, Joseph F. Maher, et al.


  • Vascular closure after transfemoral transcatheter aortic valve replacement: Further randomized trials are justified

    by William B. Hillegass

    Key Points: Major vascular complications (MVCs) occur in approximately 4% of contemporary transcatheter aortic valve replacements (TAVR) often related to large bore transfemoral access and vascular closure. Plug‐based vascular closure appears to have non‐significantly lower risk of MVCs in 8 observational studies while suture‐based devices have non‐significantly lower MVCs in the 2 randomized trials. Given the frequency of TAVR and the consequences of MVCs, larger randomized trials may better inform patient, procedural, and operator/institutional specific choice of vascular closure device.

  • Open Access

    Assessing the effects of therapeutic combinations on SARS-CoV-2 infected patient outcomes: A big data approach

    by Hamidreza Moradi, H. Timothy Bunnell, Bradley S. Price, Maryam Khodaverdi, Michael T. Vest, James Z. Porterfield, Alfred J. Anzalone, Susan L. Santangelo, Wesley Kimble, Jeremy Harper, et al.

    Background: The COVID-19 pandemic has demonstrated the need for efficient and comprehensive, simultaneous assessment of multiple combined novel therapies for viral infection across the range of illness severity. Randomized Controlled Trials (RCT) are the gold standard by which efficacy of therapeutic agents is demonstrated. However, they rarely are designed to assess treatment combinations across all relevant subgroups. A big data approach to analyzing real-world impacts of therapies may confirm or supplement RCT evidence to further assess effectiveness of therapeutic options for rapidly evolving diseases such as COVID-19. Methods: Gradient Boosted Decision Tree, Deep and Convolutional Neural Network classifiers were implemented and trained on the National COVID Cohort Collaborative (N3C) data repository to predict the patients’ outcome of death or discharge. Models leveraged the patients’ characteristics, the severity of COVID-19 at diagnosis, and the calculated proportion of days on different treatment combinations after diagnosis as features to predict the outcome. Then, the most accurate model is utilized by eXplainable Artificial Intelligence (XAI) algorithms to provide insights about the learned treatment combination impacts on the model’s final outcome prediction. Results: Gradient Boosted Decision Tree classifiers present the highest prediction accuracy in identifying patient outcomes with area under the receiver operator characteristic curve of 0.90 and accuracy of 0.81 for the outcomes of death or sufficient improvement to be discharged. The resulting model predicts the treatment combinations of anticoagulants and steroids are associated with the highest probability of improvement, followed by combined anticoagulants and targeted antivirals. In contrast, monotherapies of single drugs, including use of anticoagulants without steroid or antivirals are associated with poorer outcomes. Conclusions: This machine learning model by accurately predicting the mortality provides insights about the treatment combinations associated with clinical improvement in COVID-19 patients. Analysis of the model’s components suggests benefit to treatment with combination of steroids, antivirals, and anticoagulant medication. The approach also provides a framework for simultaneously evaluating multiple real-world therapeutic combinations in future research studies.


  • Open Access

    Community risks for SARS-CoV-2 infection among fully vaccinated US adults by rurality: A retrospective cohort study from the National COVID Cohort Collaborative

    by Alfred Jerrod Anzalone, Jing Sun, Amanda J. Vinson, William H. Beasley, William B. Hillegass, Kimberly Murray, Brian M. Hendricks, Melissa Haendel, Carol Reynolds Geary, Kristina L. Bailey, et al.

    Background: While COVID-19 vaccines reduce adverse outcomes, post-vaccination SARS-CoV-2 infection remains problematic. We sought to identify community factors impacting risk for breakthrough infections (BTI) among fully vaccinated persons by rurality. Methods: We conducted a retrospective cohort study of US adults sampled between January 1 and December 20, 2021, from the National COVID Cohort Collaborative (N3C). Using Kaplan-Meier and Cox-Proportional Hazards models adjusted for demographic differences and comorbid conditions, we assessed impact of rurality, county vaccine hesitancy, and county vaccination rates on risk of BTI over 180 days following two mRNA COVID-19 vaccinations between January 1 and September 21, 2021. Additionally, Cox Proportional Hazards models assessed the risk of infection among adults without documented vaccinations. We secondarily assessed the odds of hospitalization and adverse COVID-19 events based on vaccination status using multivariable logistic regression during the study period. Results: Our study population included 566,128 vaccinated and 1,724,546 adults without documented vaccination. Among vaccinated persons, rurality was associated with an increased risk of BTI (adjusted hazard ratio [aHR] 1.53, 95% confidence interval [CI] 1.42–1.64, for urban-adjacent rural and 1.65, 1.42–1.91, for nonurban-adjacent rural) compared to urban dwellers. Compared to low vaccine-hesitant counties, higher risks of BTI were associated with medium (1.07, 1.02–1.12) and high (1.33, 1.23–1.43) vaccine-hesitant counties. Compared to counties with high vaccination rates, a higher risk of BTI was associated with dwelling in counties with low vaccination rates (1.34, 1.27–1.43) but not medium vaccination rates (1.00, 0.95–1.07). Community factors were also associated with higher odds of SARS-CoV-2 infection among persons without a documented vaccination. Vaccinated persons with SARS-CoV-2 infection during the study period had significantly lower odds of hospitalization and adverse events across all geographic areas and community exposures. Conclusions: Our findings suggest that community factors are associated with an increased risk of BTI, particularly in rural areas and counties with high vaccine hesitancy. Communities, such as those in rural and disproportionately vaccine hesitant areas, and certain groups at high risk for adverse breakthrough events, including immunosuppressed/compromised persons, should continue to receive public health focus, targeted interventions, and consistent guidance to help manage community spread as vaccination protection wanes.


  • Open Access

    Risk of Postdischarge Bleeding From Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Among US Black and White Adults

    by Brittain Heindl, Stephen Clarkson, Vibhu Parcha, Chrisly Dillon, Renuka Narayan, Ebikere Usifo, William Hillegass, Marguerite R. Irvin, Pankaj Arora, Guihua Zhai, et al.

    Background: Dual antiplatelet therapy after percutaneous coronary intervention reduces myocardial infarctions but increases bleeding. The risk of bleeding may be higher among Black patients for unknown reasons. Bleeding risk scores have not been validated among Black patients. We assessed the difference in bleeding risk between Black and White patients along with the performance of the Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Anti Platelet Therapy, Patterns of Nonadherence to Antiplatelet Regimens in Stented Patients, and Academic Research Consortium for High Bleeding Risk scores among both groups. Methods and Results: This was a single‐center prospective study of patients who underwent percutaneous coronary intervention (2014–2019) and were followed for 1 year. The outcome was postdischarge Bleeding Academic Research Consortium 2 to 5 bleeding. Incidence rates were reported. Cox proportional hazards models measured the effect of self‐reported Black race on bleeding and determined the predictors of bleeding among 19 a priori variables. The 3 risk scores were assessed among Black and White patients separately using the Harrell concordance index. Of 1529 included patients, 342 (22.4%) self‐reported as being Black race. Unadjusted bleeding rates were 22.7 per 100 person‐years among Black patients versus 16.3 among White patients (hazard ratio, 1.41 [95% CI, 1.00–2.00], P =0.052). Predictors of bleeding were age, glomerular filtration rate 2 , prior bleeding, ticagrelor or prasugrel use, and anticoagulant use. Among Black and White patients, respectively, the C‐indexes were the following: 0.644 versus 0.600 for Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Anti Platelet Therapy ( P P =0.003 and P P =0.006 and P <0.001, respectively). Conclusions: The risk of dual antiplatelet therapy–associated postdischarge Bleeding Academic Research Consortium 2 to 5 bleeding was not significantly different between self‐reported Black and White patients. Bleeding risk scores performed similarly among both groups.


  • Ticagrelor monotherapy after coronary stenting in patients requiring proton pump inhibitor and prolonged antiplatelet therapy

    by Kellan E. Ashley, William B. Hillegass

    Key Points: Approximately half of patients undergoing coronary stenting are discharged on a proton‐pump inhibitor (PPI). Post‐hoc analysis of the large GLOBAL LEADERs trial finds PPI treatment and aspirin monotherapy after a year of dual antiplatelet therapy (DAPT) is associated with increased risk of ischemic events. In contrast, PPI treatment and continued ticagrelor monotherapy are not associated with increased ischemic events in the second year after stenting. This observational evidence suggests the GLOBAL LEADERS tested ticagrelor monotherapy regimen could be considered in patients requiring both prolonged antiplatelet therapy (>12 months) and PPI for increased bleeding risk.